Novozymes A/S
NSIS-B
Rank in Stocks
#821
Established in 1925 and based in Bagsvaerd, Denmark, Novozymes A/S is a global... Established in 1925 and based in Bagsvaerd, Denmark, Novozymes A/S is a global provider of biological solutions, specializing in the development and sale of industrial enzymes, microorganisms, and probiotics. The company's reach extends internationally, serving markets in Denmark, the rest of Europe, North America, Asia Pacific, the Middle East, Africa, and Latin America. Novozymes' diverse portfolio includes protein solutions for the food and beverage sector, alongside a comprehensive suite of cleaning and hygiene offerings for industrial, medical, and household applications, such as drain openers, septic tank treatments, ware washing, and professional laundry. In agriculture, they supply solutions for various crops like corn, cotton, soybeans, and wheat, focusing on bioyield and biocontrol, in addition to animal health and nutrition products and aquaculture systems for warm water species. The company actively supports sustainable industrial processes with contributions to bioenergy (including ethanol, biodiesel, renewable diesel, biogas, and wastewater treatment), biorefining (encompassing fiber modification, bleach boosting, deposit control, starch modification, carbon capture), and applications for textiles and leather. Their extensive range of enzyme solutions, such as lipases, proteases, oxidoreductases, and carbohydrases, are crucial for processes like corn and wheat separation, liquefaction, and saccharification. Furthermore, Novozymes addresses human health with solutions targeting brain, oral, protective, immune, and gastrointestinal well-being, while also engaging in areas like biocatalysis, cell culture, and diagnostics.
Share Price
$71.08
Market Cap
$29.32B
Change (1 day)
1.13%
Change (1 year)
11.94%
Country
DK
Trade Novozymes A/S (NSIS-B)
Category
Basic Materials
P/E ratio for Novozymes A/S (NSIS-B)
P/E ratio as of 2026 TTM: 0
According to Novozymes A/S latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is 0. At the end of 2026 the company had a P/E ratio of 0.
P/E ratio history for Novozymes A/S from 2013 to 2026
P/E ratio at the end of each year
| Year | P/E Ratio | Change |
|---|---|---|
| 2025 | 326.24 | -11.95% |
| 2024 | 370.50 | 998.99% |
| 2023 | 33.71 | 26.36% |
| 2022 | 26.68 | -43.78% |
| 2021 | 47.46 | 36.79% |
| 2020 | 34.69 | 17.17% |
| 2019 | 29.61 | 13.36% |
| 2018 | 26.12 | -22.71% |
| 2017 | 33.79 | 39.62% |
| 2016 | 24.20 | -33.23% |
| 2015 | 36.25 | 11.90% |
| 2014 | 32.39 | -1.93% |
| 2013 | 33.03 | 0.00% |
P/E ratio for similar companies or competitors
| Company | P/E Ratio | P/E Ratio Difference | Country |
|---|---|---|---|
| 31.66 | - |
GB
|
|
| 29.55 | - |
FR
|
|
| 29.64 | - |
US
|
|
| 38.39 | - |
US
|
|
| -1.46K | - |
US
|
How to read a P/E ratio?
The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share.
A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.
Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.
Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.